Conversion Right Triggered for LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Oct 04, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C., Sep 13, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today that for the period of September 12, 2010 to March 11, 2011, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp Enters into Definitive Agreement to Acquire Genzyme Genetics

BURLINGTON, N.C., Sep 13, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp(R)) (NYSE: LH), today announced that it has entered into a definitive agreement under which LabCorp will acquire Genzyme Genetics, a business unit of Genzyme Corp.

LabCorp is Scheduled to Present at the Bank of America Merrill Lynch Investment Conference

BURLINGTON, N.C., Sep 08, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE:LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Bank of America Merrill Lynch Investment Conference in San Francisco, CA.

LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference

BURLINGTON, N.C., Sep 07, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City, NY.

LabCorp Enhances HCV Testing Services with the Launch of IL-28B Test

Assay is Commercially Available for Patient Testing and Clinical Trials BURLINGTON, N.C., Aug 23, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the nationwide availability of a genetic test to detect the presence of a single

LabCorp Establishes Global Clinical Trials Collaboration with Clearstone Central Labs

BURLINGTON, N.C., Aug 12, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today a collaboration between Esoterix Clinical Trials Services, a division of LabCorp, and Clearstone Central Laboratories, a global central laboratory specializing

LabCorp Announces $250 Million Stock Repurchase Program

BURLINGTON, N.C., Aug 09, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced that its Board of Directors has authorized a new stock repurchase program under which LabCorp may purchase up to an additional aggregate of $250 million of its Common Stock

Laboratory Corporation of America(R) Holdings Announces 2010 Second Quarter Results

Strong Revenue Growth Drives Increase of 12.3% in EPS and 18.5% in Operating Cash Flow BURLINGTON, N.C., Jul 22, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced results for the quarter ended June 30, 2010.

Conversion Right Triggered For LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Jul 01, 2010 (BUSINESS WIRE) -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and